An analysis of a 206-patient randomized trial presented at the American Urological Association meeting showed use of NeoTract's UroLift prostate urethral lift for treating benign prostate disease led to durable improvement in quality of life, symptoms and urinary flow, which remained 44% higher than baseline values, after five years. Treatment did not result in the development of new-onset sexual dysfunction, and the annual rate of patients needing retreatment averaged between 2% and 3%.